Waters shareholders approve BD biosciences unit combination

Waters Corporation (NYSE: WAT) shareholders voted to approve the issuance of shares in connection with the proposed combination of Becton, Dickinson and Company's (NYSE: BDX) Biosciences & Diagnostic Solutions business with Waters, the company announced January 27.

At a special meeting, approximately 99% of shares present voted in favor of the transaction. The preliminary results will be certified by inspectors and reported in a Form 8-K filing with the Securities and Exchange Commission.

"We appreciate the continued support of our shareholders as we move closer to completing this transaction," said Udit Batra, Waters' president and chief executive officer.

BD received a favorable Private Letter Ruling from the Internal Revenue Service regarding U.S. federal income tax consequences of the transaction. Waters and BD have obtained all required regulatory approvals.

The transaction is expected to close February 9, 2026, subject to satisfaction of remaining customary closing conditions.

Waters will release its Q4 2025 financial results and hold its earnings conference call on February 9 at 8:30 a.m. Eastern Time, coinciding with the expected transaction close. The webcast will be available on the company's investor relations website.

Waters is a global provider of analytical instruments, separations technologies, and software serving life, materials, food, and environmental sciences. The company operates in over 100 countries with more than 7,600 employees.

You May Also Be Interested In